HBM Healthcare Investments Reports Strong Half-Year Results

HBM Healthcare Investments AG released its Half-Year Report for the 2026/2027 financial year, posting a profit of CHF 177 million. The net asset value (NAV) surged by 9.8%, while the share price increased by 7.8%. The company continued its share buy-back program, acquiring 67,016 shares at CHF 16.1 million.

Private companies significantly contributed with a value increase of CHF 138 million, driven by acquisitions and successful IPOs. In public markets, despite initial recovery, a consolidation phase followed, adding CHF 111 million in value predominately from high-revenue companies.

Four new private investments amounted to CHF 29 million, while USD 15 million was allocated to Crystalys and Lytica Therapeutics. Although market conditions have grown volatile due to rising US interest rates, HBM Healthcare foresees continued strategic acquisitions.